NCT03890146 (CAPIVEIN) is a clinical trial in Biochemical Dysfunction, sponsored by Fondation Ophtalmologique Adolphe de Rothschild.

Who is sponsoring NCT03890146?

NCT03890146 is sponsored by Fondation Ophtalmologique Adolphe de Rothschild.

What condition does NCT03890146 study?

NCT03890146 studies Biochemical Dysfunction.

Is NCT03890146 still recruiting?

NCT03890146 is currently terminated. Last updated 29 January 2021.

Last reviewed 2021-01-29 · How we verify

NCT03890146: CAPIVEIN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Concordance of Capillary Blood Biological Samples With Conventional Venousbiological Blood Samples.

Terminated Last updated 29 January 2021

What this trial tests

trial in Biochemical Dysfunction in 1 participant. Terminated before completion.

Timeline

20 December 2018

Primary endpoint
20 December 2020

21 December 2020

Quick facts

Lead sponsor	Fondation Ophtalmologique Adolphe de Rothschild
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	1
Start date	20 December 2018
Primary completion	20 December 2020
Estimated completion	21 December 2020
Sites	1 location across France

Conditions studied

Biochemical Dysfunction — all drugs for Biochemical Dysfunction →

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild — full company profile →

Who can join

18 and older, any sex, with Biochemical Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objectives are to evaluate the concordance between the results of natremia, kalaemia and blood sugar levels obtained 1) by capillary puncture, analysed on a delocalized resuscitation machine GEM 4000 (Werfen) and 2) by venous sampling, analysed on the machine of the standard biology laboratory Gen. 2 COBAS (Roche).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Biochemical Dysfunction

Currently open trials in the same condition.

NCT05573997 — Novel Echocardiographic Biomarkers Assessing the Myocardial Work in Heart Failure · recruiting

Other Fondation Ophtalmologique Adolphe de Rothschild trials

Trials by the same sponsor.

NCT04701619 — Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE) · NA · not yet recruiting
NCT04763161 — Immuno-inflammation in the Acute Phase of an Ischaemic Cerebral Accident Managed by Decompressive Hemicraniectomy: a Cas · not yet recruiting
NCT06264531 — Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous M · Phase 2, PHASE3 · recruiting
NCT06895044 — Evolution of Ocular Growth in Myopic Children: A Prospective Cohort Study · recruiting
NCT06644196 — Creation of a Database of Images of the Eye With the Holographic Doppler Laser · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03890146 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondation Ophtalmologique Adolphe de Rothschild
Last refreshed: 29 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03890146.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing